Dr Libertad Holazo Escalante, MD | |
324 W Main St, Crisfield, MD 21817 | |
(410) 968-3400 | |
(410) 968-3401 |
Full Name | Dr Libertad Holazo Escalante |
---|---|
Gender | Female |
Speciality | Pediatrics |
Location | 324 W Main St, Crisfield, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1841205242 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | D0026101 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Libertad Holazo Escalante, MD 324 W Main St, Crisfield, MD 21817 Ph: (410) 968-3400 | Dr Libertad Holazo Escalante, MD 324 W Main St, Crisfield, MD 21817 Ph: (410) 968-3400 |
News Archive
In this work, Dr. Diana and fellow researchers propose a low cost technique able to produce microfluidic devices for biomedical applications. The most common technique to fabricate biomedical microdevices is soft-lithography. However, it is a costly and time-consuming technique. Progress in manufacturing milling tools smaller than 100 µm, has enabled the use of micromilling machines to fabricate microfluidic devices capable of performing cell separation.
Some intensive care patients develop post-traumatic stress syndrome (PTSD) after the trauma of a difficult hospital stay, and this is thought to be exacerbated by delusional or fragmentary memories of their time in the intensive care unit. Now researchers writing in BioMed Central's open access journal Critical Care have found that if staff and close relatives make a diary for patients, featuring information about their stay and accompanied by photographs, PTSD rates can be significantly reduced.
Prostate cancer is one of the most common cancers in America and may lead to more than 32,000 deaths this year. Medical Doctor and cancer expert, Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer.
They found that the anti-cancer drug imatinib mesylate — commercially known as Gleevec and produced by Novartis Pharmaceuticals — can target a gene critical to controlling the disease process. Previously, there had been no treatment and patients usually did not survive beyond three years of diagnosis. Now the treatment is undergoing clinical trials at Mayo Clinic.
Cancer Research Technology Limited announced today that they have entered into a worldwide license agreement with TriPath Imaging, Inc.
› Verified 5 days ago